Kardigan’s $1.4bn IPO plan tests investor appetite for late-stage cardiovascular biotech
Find out how Kardigan’s planned Nasdaq IPO could reshape precision cardiovascular drug development and biotech investor sentiment.
Pharma & Biotech
Pharma & Biotech
Bayer’s asundexian FDA priority review puts Factor XIa inhibition closer to a real stroke prevention test
Bayer needs a new cardiovascular growth engine. Asundexian’s FDA priority review now tests whether Factor XIa can move from promise to practice.